Sino Biopharmaceutical (HK:1177) has released an update.
Sino Biopharmaceutical’s KRAS G12C Inhibitor, Garsorasib Tablet (D-1553), has been recognized in China’s Breakthrough Therapeutic Designation process for treating specific advanced cancers with high mortality rates. This inclusion will expedite the phase II clinical studies in China for pancreatic and colorectal cancers with the KRAS G12C mutation, addressing an urgent unmet clinical need. The company anticipates early drug launch to improve patient outcomes in these difficult-to-treat cancers.
For further insights into HK:1177 stock, check out TipRanks’ Stock Analysis page.
